Hidroferol Choque (Calcifediol)

Hidroferol Choque is used to address conditions related to insufficient vitamin D status and calcium balance.

• Treatment of documented vitamin D deficiency.
• Prevention of hypocalcemia in individuals with low calcium intake.
• Support of bone mineralization in adults at risk of osteopenia or osteoporosis.
• Adjunct therapy for chronic kidney disease patients with impaired conversion to active vitamin D.
• Maintenance of normal serum calcium and phosphate levels in persons with limited sun exposure.

• Calcifediol is the 25‑hydroxy form of vitamin D3 that circulates in the bloodstream. It is converted by the renal 1‑alpha‑hydroxylase enzyme into the hormonally active 1,25‑dihydroxyvitamin D, which binds the nuclear vitamin D receptor (VDR). Activation of VDR regulates gene transcription, increasing synthesis of calcium‑binding proteins in the intestinal epithelium and thereby enhancing absorption of calcium and phosphate from the gut.

Adverse reactions reported with calcifediol-containing products are generally mild, but rare serious events may occur.

Common

• Mild gastrointestinal discomfort such as nausea, abdominal cramping, or loose stools, typically resolving without intervention.
• Transient headache or light‑headed feeling that usually subsides within a few hours.
• Slight, asymptomatic rise in serum calcium levels detected on routine laboratory testing.
• General fatigue or mild drowsiness, especially after the first dose.

Serious

• Hypercalcemia characterized by nausea, vomiting, excessive thirst, polyuria, and possible cardiac rhythm disturbances, requiring medical evaluation.
• Hypercalciuria that may promote kidney stone formation or renal colic, necessitating monitoring.
• Allergic skin reactions including rash, pruritus, or urticaria, which may progress if exposure continues.
• Rare anaphylactic reaction presenting with airway swelling, hypotension, and systemic symptoms, demanding immediate emergency care.

When considering Hidroferol Choque, certain safety considerations should be reviewed to minimize risk.

• Avoid use in individuals with known hypercalcemia or hypervitaminosis D.
• Caution in patients with renal impairment; monitor calcium and phosphate levels.
• Not recommended for infants, children, or pregnant women without medical supervision.
• Assess baseline serum calcium, phosphate, and vitamin D status before initiating therapy.
• Concomitant use with thiazide diuretics may increase calcium levels; monitor accordingly.
• Adjust dose or discontinue if persistent elevated calcium is observed.

Calcifediol may affect the pharmacokinetics or pharmacodynamics of several other agents.

Avoid

• High‑dose vitamin D analogues or calcitriol, which can cause additive hypercalcemia.
• Thiazide or loop diuretics that alter calcium excretion.
• Orlistat, which may reduce absorption of fat‑soluble vitamins.

Use with caution

• Calcium supplements, as combined use may raise serum calcium.
• Anticonvulsants (e.g., phenobarbital, phenytoin) that increase vitamin D metabolism, potentially reducing efficacy.
• Glucocorticoids that accelerate vitamin D catabolism, possibly requiring dose adjustment.
• Bisphosphonates, where altered calcium balance may affect bone turnover monitoring.